Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Review Improvements Not Expected Until FY 2005 Under MDUFMA

This article was originally published in The Silver Sheet

Executive Summary

MEDICAL DEVICE USER FEES are expected to lead to a 25% reduction in premarket review times at the end of five years. Under the "Medical Device User Fee and Modernization Act," signed by President Bush Oct. 26, manufacturers will pay FDA a range of fees – from $154,000 for PMA reviews to $2,187 for 510(k)s – in return for the agency’s commitment to meet increasingly strict cycle review and decision goals as the program matures. Fees will fund a number of review-related activities, including pre-approval inspections, clinical trial monitoring and standards development. The Center for Devices and Radiological Health has assigned various teams to begin implementing the new program and to assess how user fees will affect operations across the center

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts